NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
62175-0242-24 | 62175-0242 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 10, 2016 | In Use | |
62175-0243-19 | 62175-0243 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 10, 2016 | In Use | |
62175-0243-24 | 62175-0243 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 10, 2016 | In Use | |
62175-0244-19 | 62175-0244 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 10, 2016 | In Use | |
62175-0244-24 | 62175-0244 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 10, 2016 | In Use | |
62175-0245-19 | 62175-0245 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 10, 2016 | In Use | |
62175-0245-24 | 62175-0245 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb. 10, 2016 | In Use | |
68788-7892-01 | 68788-7892 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | April 23, 2021 | May 30, 2023 | No Longer Used | |
68788-7892-03 | 68788-7892 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | April 23, 2021 | May 30, 2023 | No Longer Used | |
68788-7892-06 | 68788-7892 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | April 23, 2021 | May 30, 2023 | No Longer Used | |
68788-7892-09 | 68788-7892 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | April 23, 2021 | May 30, 2023 | No Longer Used | |
70934-0927-30 | 70934-0927 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 24, 2021 | In Use | ||
70934-0927-90 | 70934-0927 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 24, 2021 | In Use | ||
76388-0713-25 | 76388-0713 | Busulfan | Myleran | 2.0 mg/1 | Chemotherapy | Alkylating Agent | Alkylsulfonate | Oral | March 21, 1985 | June 30, 2023 | No Longer Used |
70534-0002-01 | 70534-0002 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Nov. 21, 2019 | In Use | ||
70534-0001-00 | 70534-0001 | Paclitaxel | Paclitaxel | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 27, 2022 | In Use | |
68788-8082-01 | 68788-8082 | Methylprednisolone Acetate | Medroloan SUIK | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Soft Tissue | Oct. 11, 2021 | In Use | |
68001-0563-84 | 68001-0563 | Cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Feb. 20, 2023 | In Use | |
68001-0482-25 | 68001-0482 | Palonosetron Hydrochloride | Palonosetron | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan. 25, 2021 | June 30, 2023 | No Longer Used |
67457-0920-05 | 67457-0920 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Oct. 12, 2020 | May 31, 2021 | In Use | |
67457-0579-01 | 67457-0579 | Melphalan Hydrochloride | Melphalan Hydrochloride | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Sept. 29, 2014 | May 31, 2021 | In Use | |
63629-2068-01 | 63629-2068 | IMATINIB MESYLATE | IMATINIB MESYLATE | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb. 8, 2019 | June 30, 2023 | No Longer Used |
68071-3268-01 | 68071-3268 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 23, 2017 | In Use | |
68071-3268-02 | 68071-3268 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 23, 2017 | In Use | |
68071-3268-07 | 68071-3268 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 23, 2017 | In Use |
Found 10,000 results in 5 milliseconds — Export these results